Jumpcan Pharmaceutical Group Co., Ltd.
Jumpcan Pharmaceutical Group Co., Ltd. (600566.SH) is a Chinese national high-tech enterprise integrating pharmaceutical R&D, manufacturing and commercial operations, with business spanning pharmaceuticals and daily chemicals.
Last updated October 12, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Jumpcan Pharmaceutical Group Co., Ltd. (600566.SH) is a national high-tech enterprise and national technology innovation demonstration enterprise that integrates product R&D, manufacturing and commercial operations. It is listed among China's top 100 pharmaceutical industry enterprises and among China's top 10 most investment-worthy pharmaceutical listed companies. Its main business covers pharmaceuticals and daily chemicals, focusing on core therapeutic areas including respiratory, pediatrics, digestion, women's health, skin health and cardiovascular, with multiple exclusive varieties and exclusive dosage forms holding leading market positions. Guided by the vision of "co-creating happy and wonderful life experiences," it provides accessible and diversified solutions oriented to clinical medication and daily health needs. It reports 4,000+ employees, 20+ billion yuan in new drugs under research, 100+ authorized patents and 80+ authorized invention patents.
History
Jumpcan Pharmaceutical Group Co., Ltd. (600566.SH) is described on its official site as a national high-tech enterprise and national technology innovation demonstration enterprise integrating product R&D, manufacturing and commercial operations, ranked among China's top 100 pharmaceutical industry enterprises and China's top 10 most investment-worthy pharmaceutical listed companies. Its main business covers pharmaceuticals and daily chemicals, focusing on core therapeutic areas including respiratory, pediatrics, digestion, women's health, skin health and cardiovascular, with multiple exclusive varieties and exclusive dosage forms holding leading market positions. The company states its vision as "co-creating happy and wonderful life experiences" and positions itself around clinical medication and daily health needs. Its disclosed figures include 4,000+ employees, 20+ billion yuan in new drugs under research, 100+ authorized patents and 80+ authorized invention patents. In 2026, its products Pudilan Xiaoyan Oral Liquid and Xiao'er Chiqiao Qingre Granules (Tongbei) were both listed on the "2026 Healthy China Brand List" and the "2026 Healthy China Brand Value List" released at the 19th Health Industry Ecology Conference (Xipu Conference) in Boao, Hainan.
- 2026
The pediatric Chinese patent medicine Xiao'er Chiqiao Qingre Granules (Tongbei) was included in the national essential medicines list.
- 2026
Three Jumpcan products — Pudilan Xiaoyan Oral Liquid, Xiao'er Chiqiao Qingre Granules (Tongbei) and Jianwei Xiaoshi Oral Liquid — were named to the 2025–2026 China Pharmacy Selected Brands list.
- 2013
Jumpcan Pharmaceutical was listed (the company's official profile lists 2013 as its listing year).
Products and positioning
National high-tech enterprise and national technology innovation demonstration enterprise; ranked among China's top 100 pharmaceutical industry enterprises and China's top 10 most investment-worthy pharmaceutical listed companies.
Pudilan Xiaoyan Oral Liquid
A product of Jumpcan Pharmaceutical; listed on the "2026 Healthy China Brand List" and the "2026 Healthy China Brand Value List."
Xiao'er Chiqiao Qingre Granules (Tongbei)
A product of Jumpcan Pharmaceutical; listed on the "2026 Healthy China Brand List" and the "2026 Healthy China Brand Value List."
Controversies
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/济川药业集团有限公司 · Editorial policy · How profiles are compiled